|
Mutation Information
|
Mutation Site
|
H51H |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
IN |
|
Genotype/Subtype
|
B;AG |
|
Viral Reference
|
AF324493.2;
AF096341.1 |
|
Relevant Drug
|
dolutegravir (DTG);cabotegravir (CAB);elvitegravir (EVG);bictegravir (BIC) |
|
Country
|
Canada |
Literature Information
|
PubMed PMID
|
30119633
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2018 |
|
Journal
|
Retrovirology |
|
Title
|
Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. |
|
Author
|
Oliveira M,Ibanescu RI,Anstett K,Mésplède T,Routy JP,Robbins MA,Brenner BG,Montreal Primary HIV (PHI) Cohort Study Group. |
|
Evidence
|
With BIC or DTG, the acquisition of solitary resistance mutations, including R263K (n = 8), S153Y/F (n = 3) or H51H/Y (n = 1) negatively impacted on viral fitness, precluding drug-dose escalations beyond 0.005–0.025 µM.
|
|
|
HIV Mutation Detail Information